Clinical trial
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients…
NCT00097968 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00097968 |
|---|---|
| Title | Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy |
| Official title | An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral® in Cardiac Transplant Recipients With Established Allograft Vasculopathy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft Rejection |
| Intervention type | Drug |
| Interventions | everolimus |
| Start date | Aug 1, 2004 |
| Primary completion | Apr 1, 2005 |
| First posted | Dec 2, 2004 |
| Last update posted | Jul 12, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: